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Identity 
Other names: EWS 




Spans 32.5 kb, in a centromere to telomere direction on 
plus strand; transcript of 2654 bp from 17 exons for the 
canonical form, with a coding sequence of 1971 nt. 
Transcription 
According to Ensembl, there are 25 transcripts, of 
which 16 different transcripts code for proteins. 
Protein 
Description 
656 amino acids for the canonical form identified in 
1993 (Plougastel et al., 1993), 68.5 kDa. From N-term 
to C-term: a transactivation domain (TAD) containing 
multiple degenerate hexapeptide repeats (consensus 
SYGQQS) (glycine, glutamine, serine, tyrosine rich or 
SYGQ rich, where the tyrosine is mandatory): amino 
acids 1 to 285, with a site interacting with SF1 from aa 
228 to 264 and an IQ domain, which binds calmodulin 
(aa 256-285), 3 arginine/glycine rich domains (RGG 
regions) (aa 300-340, 454-513 (arginine/glycine/proline 
rich), and aa 559-640), a RNA recognition motif (RRM 
or RNA-binding domain (RBD): aa 361-447), and a 














EWSR1 is ubiquitely expressed (Alliegro and Alliegro, 
1996; Andersson et al., 2008). In particular, EWSR1 is 
required for cell survival in the central nervous sy tem 
(Azuma et al., 2007). 
Localisation 
Mainly in the nucleus. It has also been found in the
cytoplasm, and associated with the plasma membrane. 
Expression of EWSR1 in the various subcellular 
compartments is affected by the methylation state of its 
RNA-binding domain (Belyanskaya et al., 2003).  
EWSR1 is mainly found in the nucleus, and more 
rarely in the cytoplasm than its two homologs FUS and
TAF15; the 3 proteins participate in nucleo-
cytoplasmic shutlling; EWSR1 localized poorly in 
stress granules when cells were exposed to 
environmental stress (stress granules are cytoplasmic 
particles composed of translation pre-initiation 
complexes, mRNAs and RNA-binding proteins) 
(Andersson et al., 2008), in Cajal bodies, and nucloli. 
Localization of EWSR1 in different subcellular 
compartments reflects a dynamic distribution during 
cell cycle: predominant nuclear localization in 
interphase cells, perichromosomal localization in 
prometaphase cells, and cytoplasmic localization in 
metaphase cells, association with microtubules in 
quiescent cells (Leemann-Zakaryan et al., 2009). 
Function 
RNA binding protein, single strand DNA binding.  
Role in transcriptional regulation for specific genes and 
in mRNA splicing: Transcription and pre-mRNA 
slicing, a post-transcriptional activity, are closely 
related. 
EWSR1 plays a role in transcription initiation: EWSR1 
is able to associate with the basal transcription factor 
TFIID (a multiprotein complex composed of the 
TATA-binding protein (TBP) and TBP-associated 
factors (TAFIIs)) and the RNA polymerase II complex. 
EWSR1 acts as a transcriptional activator (Bertoloti et 
al., 1998). It associates with heterogeneous RNA-
binding proteins (hnRNPs), such as RBM38 and 
RBM39 (RNA binding motif proteins 38 and 39, 20q13 
and 20q11 respectively) (Zinszner et al., 1994). 
EWSR1 associates with EP300 and CREBBP. EWSR1 
functions as a co-activator of CREBBP-dependent 
transcription factors. EWSR1-EP300/CREBBP 
mediates FOS activation, as well as HNF4 genes 
activation (Rossow and Janknecht, 2001; Araya et al., 
2003). CREBBP is a transcription co-activator which 
enables the interaction between various transcription 
factors and RNA Pol II, brings enzymes to the 
promoter, and remodels the chromatin favouring the 
open status (Gervasini, 2009).  
EWSR1 also activates other transcription factors such 
as POU4F1 (or BRN3A, 13q13) (Gascoyne et al., 
2004), POU5F1 (or OCT4, 6p21) (Lee et al., 2005). 
SF1 (splicing factor 1, 11q13, also called ZFM1) 
represses the transactivation domain of EWSR1; SF1,a 
transcription activator or repressor involved with many 
pathways, may negatively modulate transcription of 
target genes coordinated by EWSR1 (Zhang et al., 
1998). 
EWS functions as a docking molecule by recruiting 
serine-arginine (SR) splicing factors such as SRSF10 
(serine/arginine-rich splicing factor 10, 1p36, or TASR, 
which represses pre-mRNA splicing) to RNA Pol II, 
coupling gene transcription to RNA splicing by binding 
to hyperphosphorylated RNA Pol II through its N-term 
part domain, and SR splicing factors through its C-term 
domain (Yang et al., 2000). 
YBX1 (Y box binding protein 1, 1p34), a 
multifunctional protein that shuttles between the 
cytoplasm (where it binds to mRNA and regulates 
mRNA translation) and the nucleus (where it regulates 
transcription of diverse target genes), interacts wi h the 
C-term domain of EWS. This interaction docks YBX1 
to RNA Pol II to participate in pre-mRNA splicing 
(Chansky et al., 2001). 
SMN1 (survival of motor neuron 1, telomeric, 5q13) 
plays a major role in the pre-mRNA splicing machinery 
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(role in spliceosomal snRNP assembly in the cytoplasm 
and in pre-mRNA splicing in the nucleus) (Pellizzoni et 
al., 1998). SMN1, through its Tudor region, binds the 
RG1 region of EWSR1 (Young et al., 2003). 
RNU1-2 (RNA, U1 small nuclear 2, 1p36, also called 
U1C), another splicing protein, also interacts with 
EWSR1 (Knoop and Baker, 2000). 
EWSR1 is phosphorylated by PRKC (protein kinase C) 
though its IQ domain, which inhibits RNA binding of
EWSR1; CALM (calmodulin) binding to EWSR1 
inhibits PRKC phosphorylation (Deloulme et al., 
1997). 
EWSR1 interacts with POU4F2 (4q31), a gene which 
regulates differentiation of neuronal cells (Gascoyne et 
al., 2004). EWSR1 interacts with LMNA (lamin A/C, 
1q22, a component of the nuclear envelope which 
interacts with DNA, histones and transcriptional 
repressors) is essential for pre-B lymphocyte 
development and, during meiosis, in XY pairing and in 
meiotic recombination, as cross-overs are reduced in 
ews-/- spermatocytes. Loss of EWSR1 results in 
premature cellular senescence (Li et al., 2007). EWSR1 
is required for proper localization of aurora B during 
mitosis, and maintains mitotic spindle integrity (Azuma 
et al., 2007). 
It also interacts with BARD1 (BRCA1 associated 
RING domain 1) (Spahn et al., 2002). 
EWSR1 and CCNL1 (cyclin L1, 3q25), are interacting 
partners of TFIP11 (tuftelin-interacting protein 11, 
22q12), a protein functionally related to the 
spliceosome and involved in pre-mRNA splicing) 
(Tannukit et al., 2008). 
Homology 
Member of the TET family of RNA binding proteins, 
with FUS (TLS) and TAF15 (TAFII68). TET is for Tls, 
Ewsr1, TafII68). TET proteins contain specific 
structural domains not found elsewhere in other RNA 
binding proteins, i.e. a N-term SYGQ rich (TAD: 
transactivation domain), a conserved RNA-binding 
domain (RRM: RNA recognition motif), RG rich 
regions, and a Cys2-Cys2 Zinc finger which can bind 
nucleic acids; they are also functionally related 
(reviews in Law et al., 2006; Tan and Manley, 2009). 
Implicated in 
Various tumours (see details below) 
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Ewing's sarcoma/Peripheral 
neurectodermal tumour (ES/PNET) 
Note 
- With: t(11;22)(q24;q12) --> FLI1 - EWSR1 (Delattre 
et al., 1992; Bailly et al., 1994; Thomas et al., 1994; 
records in the Mitelman Database). 
- With: t(2;22)(q36;q12) --> FEV - EWSR1 (Llombart-
Bosch et al., 2000; Peter et al., 2001; Navarro et al., 
2002; Hattinger et al., 1999; Wang et al., 2007). 
- With: t(7;22)(p22;q12) --> ETV1 - EWSR1 (Jeon et 
al., 1995; Peter et al., 2001; Zielenska et al., 2001; 
Wang et al., 2007). 
- With: t(17;22)(q21;q12) --> ETV4 - EWSR1 (Kaneko 
et al., 1996; Urano et al., 1996; Urano et al., 1998). 
- With: t(20;22)(q13;q12) --> NFATC2 - EWSR1 
(Szuhai et al., 2009). 
- With: t(21;22)(q21;q12) --> ERG - EWSR1 (Dunn et 
al., 1994; Giovannini et al., 1994; Kaneko et al., 1997; 
Maire et al., 2008; Minoletti et al., 1998; Sorensen et 
al., 1994; Zoubek et al., 1994; Zucman et al., 1993b; 
Shing et al., 2003; Peter et al., 1996). 
- With: inv(22)(q12q12) --> PATZ1 - EWSR1 
(Mastrangelo et al., 2000) 
Note: Rare cases of ES/PNET have been described 
without EWSR1 involvement, but, instead: 
- with: t(2;16)(q35;p11) --> FUS - FEV (Navarro et al., 
2002) or, 
- with: t(16;21)(p11;q22) --> FUS - ERG (Shing et al.,
2003; Berg et al., 2009). To be noted that the same 
t(16;21)(p11;q22) has been found in rare cases of acute 
myeloid leukaemia. 
A t(11;22)(q24;q12) has also been found in a case of 
cerebellar PNET (Jay et al., 1996). 
Disease 
Ewing's sarcoma/Peripheral neurectodermal tumour 
spectrum is a group of sarcomas with small blue round 
cells with more (PNET side) or less (Ewing side) 
features of neuroectodermal differentiation. ES/PNET 
entity also includes peripheral neuroepithelioma and 
Askin tumour. These tumours display both 
mesenchymal stem cell and neural crest stem cell 
properties. It is mainly found in adolescents and young 
adults. Cytogenetics and immunochemistry are 
essential for the differential diagnosis with other 
sarcomas (review in Romeo and Dei Tos, 2010). 
Prognosis 
Prognosis has dramatically improved, from less than 
10% of long survivors, to a 5-year disease free survival 
of 75% for patients with a localized disease, and 25-
30% for those with a metastatic disease (Ludwig, 
2008). 
Cytogenetics 
The t(11;22)(q24;q12) EWSR1/FLI1 is found in 85% 
of cases of Ewing tumours. The t(21;22)(q21;q12) with 
EWSR1/ERG is the second in frequency, found in 
about 10% of cases. 
 
Hybrid/Mutated gene 
t(11;22)(q24;q12): 5' EWSR1 - 3' FLI1; breakpoints 
clustered over a 2-3 kb genomic region and over a 30-
40 kb genomic region. Various junctions between 
EWSR1 exon 7 or 10 with FLI1 exon 5, 6, or 8. In the
most common fusion type (type 1), EWSR1 exon 7 is 
fused in frame to FLI1 exon 6; in type 2, EWSR1 exon 
7 is fused in frame to FLI1 exon 5. (Obata et al., 1999; 
de Alava et al., 1998).  
t(21;22)(q21;q12): 5' EWSR1 - 3' ERG; the orientation 
of the ERG gene is from telomere to centromere, 
opposite to that demonstrated for EWSR1. 
Other translocations: 5' EWSR1 - 3' FEV; 5' EWSR1 - 
3' ETV1; 5' EWSR1 - 3' ETV4; 5' EWSR1 - 3' 
NFATC2; 5' EWSR1 - 3' PATZ1. 
Abnormal protein 
t(11;22)(q24;q12): oncogenic protein on the der(22) 
chromosome generated by fusion of the N terminal 
domain of EWSR1 protein (transactivation domain, e.g.
fusion of EWSR1 amino acids 1-265) with the DNA 
binding domain (ETS type, amino acids 281-361) of 
the human FLI1 protein, a 452 amino acids protein (.g. 
fusion from amino acids 260).  
t(21;22)(q21;q12): oncogenic protein on the der(22) 
chromosome generated by fusion of the N terminal 
domain of EWSR1 protein with DNA binding domain 
of human ERG protein.  
Other translocations: Most of the EWSR1 partners in 
ES/PNET are ETS family members (FLI1, ERG, 
ETV1, ETV4, FEV) and translocation results in the 
juxtaposition of the transactivation domain of EWSR1 
with the DNA binding domain -ETS type of the 
partner. PATZ1 is a transcription regulator with a AT
hook (DNA-binding motif), a POZ domain (mediates 
dimerisation) and Zn fingers (DNA-binding). NFATC2 
is a cytokine inducer; translocates into the nucleus to 
regulate transcription. 
Oncogenesis 
EWSR1-FLI1 is a dominant oncogene transformed 
cells by subverting normal transcriptional 
controls/FLI1 member of ETS family. The target gene 
repertoire of EWSR1-FLI1 varies according to the host 
cell type. EWSR1-FLI1 induces a TP53-dependent 
growth arrest in fibroblasts, supporting the importance 
of TP53 loss in the genesis of Ewing's tumours 
(Lessnick et al., 2002). EWSR1-FLI1 activates CASP3 
and promotes apoptosis in mouse embryonic fibroblasts 
(Sohn et al., 2010). EWSR1-FLI1 induces expression 
of the embryonic stem cell genes OCT4, SOX2, and 
NANOG in paediatric mesenchymal stem cells but not 
in adult mesenchymal stem cells. SOX2 is a target for 
EWSR1-FLI1 and miRNA145 and may be critical in 
Ewing sarcoma pathogenesis (Riggi et al., 2010). 
EWSR1-FLI1 expression in a rhabdomyosarcoma cell 
line induced upregulation of many genes involved in 
neural crest differentiation, and the cell phenotype was 
modified, resembling ewing tumour cells (Hu- 
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Lieskovan et al., 2005; Riggi et al., 2008). EZH2 is a 
target of EWSR1-FLI1. EZH2 regulates stemness and 
genes involved in neuroectodermal and endothelial 
differentiation (Richter et al., 2009). EWSR1-FLI1 
induced T-cell neoplasia in committed lymphoid cells, 
showing that the oncogenetic potential of EWSR1-FLI1 
is not restricted to pluripotent progenitors or 
mesenchymal cells (Codrington et al., 2005). EWSR1-
FLI1 in transgenic mouse induced limb developmental 
defects by disruption of the normal development of 
connective tissues; homozygous deletion of p53 in 
mice provoke sarcomas, in particular osteosarcomas, 
introduction of EWSR1-FLI1 changed the tumour 
phenotype from osteosarcomas to poorly differentiated 
sarcomas (Lin et al., 2008). It is believed that 
EW/PNET arise from mesenchymal stem cells in which 
terminal differentiation is blocked by EWSR1-FLI1 
(Tirode et al., 2007). 
Transcriptional repressors such as NKX2-2 (Smith et 
al., 2006) or NR0B1 are induced by EWSR1-FLI1. 
Furthermore, EWSR1-FLI and NR0B1 physically 
interact (Kinsey et al., 2009). The transcriptional 
complex of EWSR1-FLI1 includes RNA polymerase II, 
CREB1 (cAMP responsive element binding protein 1) 
and DHX9 (RHA, RNA helicase A) (Toretsky et al., 
2006; Erkizan et al., 2009). EWSR1-Ets proteins 
cooperatively bind DNA with FOS-JUN (Kim et al., 
2006). EWSR1-FLI1 is involved in the spliceosome 
(review in Erkizan et al., 2010). EWSR1-FLI1 chimeric 
protein, but not wild EWSR1, can oppose the change i  
splicing pattern induced by expression of hnRNPA1 
(Knoop and Baker, 2001). 
EWSR1-FLI1 (dis)regulates many pathways (Jedlicka, 
2010). CD99, a transmembrane protein highly 
expressed in Ewing sarcoma cells, has a key role in 
various biological functions, including inhibition of 
neuronal differentiation that may occur through the 
RAS/RAF/MAPK pathway in Ewing's tumours (Rocchi 
et al., 2010). PDGFC (Zwerner and May, 2001) as well
as IGF1 are induced by EWSR1-FLI1, and also by 
EWSR1-ERG or FUS-ERG (Cironi et al., 2008). GLI1 
is upregulated by EWSR1-FLI1, independently of the 
Hedgehog pathway (Beauchamp et al., 2009; Joo et al., 
2009). Expression of DKK1 (which antagonizes Wnt 
signaling) is inhibited by EWSR1-FLI1 (Navarro et al., 
2010), and DKK2 enhanced (Miyagawa et al., 2009). 
TGFbR2 is inhibited by EWSR1-FLI1 (Hahm, 1999). 
Other features were summarized in Janknecht et al., 
2005: EWSR1-FLI1 induces proliferation independent 
of exogenous growth factors (EWSR1-ETS proteins 
upregulate PDGFC and also CCND1), evasion of 
growth inhibition (downregulation of TGFbR2 may 
help cells escape growth surveillance), suppression of 
differentiation (ID2, overexpressed in Ewing tumours, 
is able to suppress differentiation of a variety of cells), 
immortality (hTERT (human telomerase reverse 
transcriptase)), limiting factor for telomerase activity  
 
and senescence, is upregulated by EWSR1-ETS fusion 
proteins), escape from apoptosis (EWSR1-FLI1 was 
shown to repress IGFBP-3, preventing apoptosis) 
(Janknecht et al., 2005). 
Desmoplastic small round cell sarcoma 
(DSRCT) 
Note 
- With: t(11;22)(p13;q12) --> WT1 - EWSR1 (Ladanyi 
and Gerald, 1994; Gerald et al., 1995; Benjamin et al., 
1996; records in the Mitelman Database). 
- With: t(21;22)(q21;q12) --> ERG - EWSR1 (Ordi et 
al., 1998). 
Disease 
Desmoplastic small round cell sarcoma is a small blue 
round cells tumour, often intra-abdominal, with a mle 
predominance, arising in children and young adults, 
with a very poor prognosis. Cytogenetics and 
immunochemistry are essential for the differential 
diagnosis with other sarcomas with small blue round 
cells. 
Cytogenetics 
Most of the cases are cases of t(11;22)(p13;q12). 
Hybrid/Mutated gene 
t(11;22)(p13;q12): 5' EWSR1 - 3' WT1; breakpoints: 
between EWSR1 exons 7 and 8 and between WT1 
exons 7 and 8. 




N terminal domain of EWSR1 fused to the Zn fingers 
of WT1. 
Clear cell sarcoma of soft 
parts/malignant melanoma of soft parts 
(CCSSP) 
Note 
- With: t(2;22)(q34;q12) --> CREB1 - EWSR1 
(Antonescu et al., 2006; Wang et al., 2009). 
- With: t(12;22)(q13;q12) --> ATF1 - EWSR1 (Zucman 
et al., 1993a; records in the Mitelman Database). 
Disease 
Clear cell sarcoma of tendons and aponeuroses affects 
young adults. It is characterized by slow progression, 
with recurrences and metastases, with only 40-50% 
long survivors. 
Hybrid/Mutated gene 
5' EWSR1 - 3' ATF1 (t(12;22)(q13;q12) cases) or, 
more rarely, 5' EWSR1 - 3' CREB1 (t(2;22)(q33;q12) 
cases). 
Abnormal protein 
N terminal domain of EWSR1 fused to the bZIP 
domain of CREB1 or ATF1. 
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Angiomatoid fibrous histiocytoma 
(AFH) 
Note 
- With: t(2;22)(q34;q12) --> CREB1 - EWSR1 
(Antonescu et al., 2007; Shao et al., 2009; Rossi et al., 
2007). 
- With: t(12;22)(q13;q12) --> ATF1 - EWSR1 
(Dunham et al., 2008; Hallor et al., 2005; Hallor et al., 
2007; Rossi et al., 2007; Tanas et al., 2010). 
Note: Cases of t(12;16)(q13;p11) with 5' FUS - 3' 
ATF1 have also been described (Raddaoui et al., 2002; 
Waters et al., 2000). 
Disease 
Angiomatoid fibrous histiocytoma is a rare soft-tissue 
tumour of low metastatic potential (local recurrenc 
below 15% of cases, and metastases occur in less than 
2% of patients); it is mostly found in children and 
young adults. Surgical excision is the treatment of 
choice. 
Hybrid/Mutated gene 
5' EWSR1 - 3' ATF1 (t(12;22)(q13;q12) cases), or 5' 
EWSR1 - 3' CREB1 (t(2;22)(q33;q12) cases). 
Abnormal protein 
N terminal domain of EWSR1 fused to the bZIP 
domain of ATF1 or CREB1. 
Extraskeletal myxoid chondrosarcoma 
(EMCS) 
Disease 
Extra-skeletal myxoid chondrosarcomas represent 
about 5% of chondrosarcomas. There is male 
predominance. It affects adults mainly, in the forties or 
the fifties. The estimated 5-, 10-, and 15-year survival 
rates were 90%, 70%, and 60%, respectively (Meis-
Kindblom et al., 1999). 
Cytogenetics 
t(9;22)(q22;q12) --> NR4A3 - EWSR1 (Labelle et al., 
1995; Brody et al., 1997). 
Note: Cases of t(3;9)(q12;q31) --> NR4A3 - TFG 
(Hisaoka et al., 2004), t(9;15)(q31;q21) --> NR4A3 - 
TCF12 (Sjögren et al., 2000), t(9;17)(q22;q11) --> 
NR4A3 - TAF15 (Sjögren et al., 1999; Attwooll et al., 
1999; records in the Mitelman Database) have also 
been reported. 
Hybrid/Mutated gene 
5' EWSR1 - 3' NR4A3 (NR4A3 is also known as TEC 
or CHN). 
Myxoid liposarcoma/round cell 
liposarcoma (MLS) 
Disease 
Myxoid liposarcoma is the most frequent type of 
liposarcoma, found in about half of the cases. It occurs 
in male and female patients equally, in their thirties to 
fifties. It has a relatively favorable prognosis; the 
variant round cell liposarcoma is much more 
aggressive. 
Cytogenetics 
A t(12;22)(q13;q12) --> DDIT3 - EWSR1 
(Panagopoulos et al., 1994) is found in 5% of cases, 
whereas a t(12;16)(q13;p11) is found in most cases. 
Hybrid/Mutated gene 
5' EWSR1 - 3' DDIT3 (also called CHOP). The 
t(12;16)(q13;p11) with 5' FUS - 3' DDIT3 is more 
frequent. 
Abnormal protein 
Fuses the N-term transactivation domain of EWSR1 
with the bZIP domain of DDIT3. 
Acute leukaemia 
Disease 
Acute lymphoblastic leukaemia (B-cell ALL), 
biphenotypic leukaemia 
Cytogenetics 
A t(12;22)(p13;q12) was found in 2 cases (Martini et 
al., 2002). Note: the equivalent t(12;17)(p13;q11) --> 
TAF15 - ZNF384 has also been found in other cases of 
the same series. 
Hybrid/Mutated gene 
5' EWSR1 - 3' ZNF384. 
Abnormal protein 
Fuses the N-term transactivation domain of EWSR1 
with the leucine-serine rich-proline-nuclear localiz t on 
signal-Kruppel-type C2H2 Zinc finger domains of 
ZNF384. 
Note 
EWSR1 involvement has also been described in a 
number of other tumours. In some instances, the 
diagnosis is unambiguous; in other cases, pathological 
diagnoses are difficult to reach, when the tumour is 
undifferentiated or polyphenotypic. 
Rhabdomyosarcoma (RMS) 
Disease 
Rhabdomyosarcomas, the most common pediatric soft 
tissue sarcomas, are tumours related to the skeletal 
muscle lineage. The 2 major subtypes are alveolar 
rhabdomyosarcoma (ARMS) and embryonal 
rhabdomyosarcoma (ERMS). Most ARMS cases are  
 
characterised by either a t(2;13)(q35;q14), resulting in a 
PAX3 - FOXO1 hybrid gene, or a t(1;13)(p36;q14) 
resulting in a PAX7 - FOXO1 hybrid gene (Reichek 
and Barr, 2009).  
However, 4 cases of RMS have been described, 
instead, with an EWSR1 rearrangement. 
Cytogenetics 
A t(4;22)(q35;q12) was found in a case of embryonal 
rhabdomyosarcoma (Sirvent et al., 2009), and a 
t(11;22)(q24;q12) in the other cases (Sorensen et al., 
1993; Thorner et al., 1996). 
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Hybrid/Mutated gene 
5' EWSR1 - 3' DUX4 in the t(4;22)(q35;q12) case, and
5' EWSR1 - 3' FLI1 in the t(11;22) cases. 
Giant cell tumour of bone 
Disease 
Locally destructive tumour, usually seen in patients 
over 20 years of age, with good prognosis, despite of 
recurrences and pulmonary metastases (Forsyth and 
Hogendoorn, 2003). 
Cytogenetics 
In giant-cell tumour of bone, the most frequent finding 
is telomeric association. One study showed that a very
minor clone with EWSR1/FLI1 translocation could be 
detected in most of the cases studied (Scotlandi et al., 
2000). 
Hybrid/Mutated gene 
5' EWSR1 - 3' FLI1. 
Myoepithelioma/myoepithelial 
carcinoma of soft parts 
Disease 
Myoepithelioma tumours of soft tissue cover a wide 
range of tumours of various behaviour. While most are 
of intermediate aggressivity, some metastase. 
Cytogenetics 
t(1;22)(q23;q12) in one case (Brandal et al., 2008), 
t(19;22)(q13;q12) in another case (Brandal et al., 
2009). 
Hybrid/Mutated gene 
5 ' EWSR1 - 3' PBX1, which fuses exons 8 from 
EWSR1 to exons 5 of PBX1 in the most benign case; 5' 
EWSR1- 3' ZNF444 in the malignant case; fuses 
EWSR1 exon 8 to the very near end of ZNF444. 
Hidradenoma of the skin 
Disease 
Hidradenoma or eccrine/apocrine acrospiroma, is a 
benign adnexal tumour developing most often in adults. 
3 cases were found with a t(6;22)(p21;q12) and/or its 
fusion transcript equivalent (Möller et al., 2008). 
Abnormal protein 
5' EWSR1 - 3' POU5F1. 
Mucoepidermoid carcinoma of the 
salivary glands 
Disease 
Mucoepidermoid carcinoma is the most common type 
of malignant salivary gland tumour, often associated 
with a t(11;19)(q21;p13) translocation with expression 
of chimeric genes 5' CRTC1 - 3' MAML2. One case of 
mucoepidermoid carcinoma was found with a 
t(6;22)(p21;q12) (Möller et al., 2008). 
Abnormal protein 
5' EWSR1 - 3' POU5F1. 
Neuroblastoma 
Disease 
Neuroblastomas are peripheral neuroblastic tumours 
derived from cells of the sympathetic nervous system. 
They occur mainly in infants and young children, with 
a median age of 1.5 years. 
Hybrid/Mutated gene 
Two patients, aged 3 years and 5.5 years, were 
described with a 5' EWSR1 - 3' FLI1 transcript in 
typical neuroblastomas with elevated urinary 
catecholamines. Prognosis had been very poor: the two 
patients relapsed during -or at the end of- treatmen  and 
died within 2 months (Burchill et al., 1997). 
Olfactory neuroblastoma 
Disease 
Olfactory neuroblastoma or esthesioneuroblastoma, is  
malignant neurectodermal tumour, from the olfactory 
neuroepithelium that typically occurs in the superior 
nasal cavity. It is keratin negative, neuroendocrine 
marker positive, and S100 positive. It arises at any age, 
often in the adult, with a 5-year survival rate above 
50% (the 5-year overall survival for patients treated for 
nonmetastatic olfactory neuroblastoma was recently 
found at 64% (Ozsahin et al., 2010)). 
Cytogenetics 
t(11;22)(q24;q12), inducing a 5' EWSR1 - 3' FLI1 
hybrid gene (Sorensen et al., 1996). However, recent 
review rejects cases with EWSR1 involvement, as 
being misdiagnosed cases of ES/PNET (Thompson, 
2009). 
Solid pseudopapillary tumour of the 
pancreas (SPTP) 
Disease 
Solid pseudopapillary tumour of the pancreas is a rare
epithelial tumour, typically occuring in young female 
patients, rarely metastasizing (Yu et al., 2010). 
Cytogenetics 
One case showed a t(11;22)(q24;q12) (Maitra et al., 
2000) 
Hybrid/Mutated gene 
5' EWSR1 - 3' FLI1. 
"Small round cell tumours", 
"polyphenotypic mesenchymal 
malignancies", and "undifferentiated 
sarcomas" 
Disease 
An undifferentiated sarcoma derived from pelvic bone 
exhibited a t(6;22)(p21;q12) with 5' EWSR1 - 3' 
POU5F1. This resulted in the fusion of exons 1-6 of 
EWSR1 and exons 2-5 and a part of exon 1 of 
POU5F1.The patient died 6 months after diagnosis 
(Yamaguchi et al., 2005). 
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A small round cell tumour was found to have a 
t(2;22)(q31;q12), with 5' EWSR1 - 3' SP3 hybrid gene; 
fuses the exon 7 of EWSR1 to exon 6 of SP3. N-term 
transactivation domain of EWSR1 fused with the Zinc 
fingers of SP3. The patient died 20 months after 
diagnosis (Wang et al., 2007).  
Other cases of spindle cell tumours, small round cell 
poorly differentiated, biphenotypic (myogenic/neural 
differentiation), or polyphenotypic sarcomas present 
with the classical t(11;22)(q24;q12) / 5' EWSR1 - 3' 
FLI1 or other variants, such as the t(2;22)(q36;q12) / 5' 
EWSR1 - 3' FEV (Wang et al., 2007), the 
t(11;22)(p13;q12) / 5' EWSR1 - 3' WT1 (Alaggio et al.,
2007), the t(12;22)(q13;q12) / 5' EWSR1 - 3' ATF1 
(Somers et al., 2005), or the t(21;22)(q21;q12) / 5' 




Clustered over a 2.3 kb genomic region. 
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